EIC Fund companies portfolio

First-in-class therapy development addressing unmet medical needs in the oncology space

A novel combination treatment effective against all multidrug-resistant pathogens deemed as a critical priority by the WHO

Developer of antithrombotic drugs for vascular complications.

Developer of dementia and dermatology drugs via genomics.

Anti-microRNAs designed for the treatment of diseases with unmet needs.

Pharmaceutical company focused on the small molecule drug NTP42 for the treatment of pulmonary arterial hypertension (PAH).

Next generation of insulin-producing cell transplantation

Disrupting the manufacturing of biological drugs through a ground-breaking nanotechnology-based microcarrier

First-in-class disease-modifying drug for chronic airway disorders

Biotechnology platform designed to create intelligence-augmenting services for precision oncology research and drug development

Developing novel treatments for medical conditions with unmet needs

Clinical-stage biotechnology disease modifying therapies for neurodegenerative diseases

Treating cancer by targeting tumor viruses within the human genome

Innovative treatments for chronic pain disorders and hearing loss.

Developer of injectable hydrogel for cartilage repair.

Next-generation biologics to treat wounds in skin and mucosa

Developing a portfolio of drug candidates to address several types of severe cancers